Corcept Therapeutics (CORT) Receivables (2012 - 2026)

Corcept Therapeutics (CORT) has 15 years of Receivables data on file, last reported at $39.1 million in Q1 2026.

• For the quarter ending Q1 2026, Receivables fell 51.17% year-over-year to $39.1 million; the trailing twelve-month figure through Mar 2026 stood at $39.1 million (down 51.17% YoY), and the FY2025 full-year result was $63.9 million, up 59.81% from the prior year.
• Receivables declined to $39.1 million in Q1 2026, from $59.8 million in the prior quarter.
• In the past five years, Receivables ranged from a high of $80.0 million in Q1 2025 to a low of $28.2 million in Q1 2022.
• A 5-year average of $50.4 million and a median of $47.5 million in 2024 frame the typical range for Receivables.
• Across the five-year window, Receivables jumped 68.4% in 2025 and sank 51.17% in 2026, its largest moves.
• Tracing CORT's Receivables over 5 years: stood at $45.1 million in 2022, then fell by 8.73% to $41.1 million in 2023, then surged by 31.26% to $54.0 million in 2024, then gained by 10.76% to $59.8 million in 2025, then plunged by 34.65% to $39.1 million in 2026.
• Business Quant data shows CORT's Receivables at $39.1 million in Q1 2026, $59.8 million in Q4 2025, and $73.5 million in Q3 2025.